Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
- 23 April 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 26 (9) , 1185-1193
Abstract
The onset and early course of schizophrenia is associated with subtle loss of grey matter which may be responsible for the evolution and persistence of symptoms such as apathy, emotional blunting, and social withdrawal. Such ‘negative’ symptoms are unaffected by current antipsychotic therapies. There is evidence that the antibiotic minocycline has neuroprotective properties. We investigated whether the addition of minocycline to treatment as usual (TAU) for 1 year in early psychosis would reduce negative symptoms compared with placebo. In total, 144 participants within 5 years of first onset in Brazil and Pakistan were randomised to receive TAU plus placebo or minocycline. The primary outcome measures were the negative and positive syndrome ratings using the Positive and Negative Syndrome Scale. Some 94 patients completed the trial. The mean improvement in negative symptoms for the minocycline group was 9.2 and in the placebo group 4.7, an adjusted difference of 3.53 (s.e. 1.01) 95% CI: 1.55, 5.51; p < 0.001 in the intention-to-treat population. The effect was present in both countries. The addition of minocycline to TAU early in the course of schizophrenia predominantly improves negative symptoms. Whether this is mediated by neuroprotective, anti-inflammatory or others actions is under investigation.Keywords
This publication has 41 references indexed in Scilit:
- Long-term Antipsychotic Treatment and Brain VolumesArchives of General Psychiatry, 2011
- The NADPH Oxidase NOX2 Controls Glutamate Release: A Novel Mechanism Involved in Psychosis-Like Ketamine ResponsesThe Journal of Neuroscience, 2010
- Neurocognitive Effectiveness of Haloperidol, Risperidone, and Olanzapine in First-Episode PsychosisThe Journal of Clinical Psychiatry, 2009
- IQ as a predictor of functional outcome in schizophrenia: A longitudinal, four-year study of first-episode psychosisSchizophrenia Research, 2009
- N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled TrialBiological Psychiatry, 2008
- Focal Gray Matter Changes in Schizophrenia across the Course of the Illness: A 5-Year Follow-Up StudyNeuropsychopharmacology, 2007
- Schizophrenia: New Pathological Insights and TherapiesAnnual Review of Medicine, 2007
- Calprotectin in microglia from frontal cortex is up‐regulated in schizophrenia: evidence for an inflammatory process?European Journal of Neuroscience, 2006
- Cognitive–behavioural therapy in first-episode and early schizophreniaThe British Journal of Psychiatry, 2004
- Chronic Administration of Haloperidol and Olanzapine Attenuates Ketamine-Induced Brain Metabolic ActivationThe Journal of Pharmacology and Experimental Therapeutics, 2003